Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia.

@article{Treon2006UpdateOT,
  title={Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia.},
  author={Steven P Treon and Morie A Gertz and Meletios Α. Dimopoulos and Athanasios Anagnostopoulos and Joan Blad{\'e} and Andrew Branagan and Ram{\'o}n Garc{\'i}a-Sanz and Stephen Lucas Miss. Johnson and Eva K Kimby and V{\'e}ronique Leblond and J P Fermand and David G Maloney and Giampaolo Merlini and Pierre Morel and Enrica Morra and Gwen Nichols and Enrique Mar{\'i}a Ocio and Roger J Owen and Marvin J. Stone},
  journal={Blood},
  year={2006},
  volume={107 9},
  pages={3442-6}
}
Waldenström macroglobulinemia (WM) is a B-cell disorder characterized by the infiltration of lymphoplasmacytic cells into bone marrow and the presence of an IgM monoclonal gammopathy. As part of the Third International Workshop on WM, held October 7 to 10, 2004 in Paris, France, a consensus panel charged with providing treatment recommendations for WM updated its recommendations on both frontline and salvage therapies. The panel considered encouraging results from recent studies that addressed… CONTINUE READING
74 Citations
51 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 74 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 51 references

Bortezomib, dexamethasone and rituximab (BDR) is a highly active regimen in the primary therapy of Waldenstrom’s macroglobulinemia: Planned interim results of WMCTG Clinical Trial 05-180

  • SP Treon, JD Soumerai, CJ Patterson
  • Blood 108:
  • 2006
Highly Influential
7 Excerpts

2-CDA-cyclophosphamide / rituximab for symptomatic WM

  • SK Thomas, KB Delasalle, M Gavino
  • Haematologica 92:PO-1227,
  • 2007

Allogeneic stem cell transplantation (ALLO-SCT) in Waldenstrom macroglobulinemia (WM): An analysis of 106 cases from the European Bone Marrow Registry (EBMT)

  • C Kyriakou, C Canals, G Taghipour
  • Haematologica 92:WM3.9,
  • 2007
1 Excerpt

Autologous stem cell transplantation (ASCT) for patients with Waldenstrom’s macroglobulinemia: An analysis of 201 cases from the European Bone Marrow Transplant Registry (EBMT)

  • C Kyriakou, C Canals, G Taghipour
  • Haematologica 92:PO-1228,
  • 2007

Fludarabine plus cyclophosphamide and rituximab (RFC) in Waldenstrom’s macroglobulinemia (WM): Results in 25 patients

  • J Vargaftig, B Pegourie-Bandelier, B Mahe
  • Haematologica 92:PO1226,
  • 2007
1 Excerpt

Fludarabine, cyclophosphamide and rituximab in Waldenstrom’s macroglobulinemia: An effective regimen requiring a new category of response criteria and a delayed assessment of results

  • A Tedeschi, S Miqueleiz, F Ricci
  • Blood 110:1290,
  • 2007

Hematopoietic stem cell transplantation (HSCT) in Waldenstrom macroglobulinemia (WM): Update of the French experience in 54 cases

  • N Dhedin, R Tabrizi, PE Bulabois
  • Haematologica 92:
  • 2007
1 Excerpt

Similar Papers

Loading similar papers…